Anticipate heightened investor interest and potential stock movement around May 21–June 2 as data is released and presented. Monitor for response rates, durability, and safety signals in the upcoming disclosures, which could influence near-term valuation. This ASCO cycle may serve as a key inflection point for Immatics’ PRAME and MAGEA programs.
Price Chart
Executive Summary
Immatics announced that four of its abstracts have been accepted for oral presentation at the 2026 ASCO Annual Meeting, featuring clinical data from its PRAME-targeted cell therapies (anzu-cel, IMA203CD8) and MAGEA4/8 bispecific (IMA401) across multiple solid tumors. The presentations include updated Phase 1b and Phase 1a/1b data in melanoma, gynecologic cancers, synovial sarcoma, and first-in-human results for IMA401. This visibility at a top oncology conference highlights clinical progress in its core pipeline programs.
Key Facts
- Four abstracts accepted for oral presentation at ASCO 2026, a high-impact oncology conference
- Data includes updated Phase 1b results for anzu-cel in advanced melanoma and Phase 1a/1b data for IMA203CD8 (GEN2) in gynecologic cancers
- First-in-human results for IMA401, a MAGEA4/8 bispecific, to be presented across multiple solid tumors
- Presentations span melanoma, gynecologic cancers, and synovial sarcoma, demonstrating broad applicability of PRAME-targeted therapies
- Full data to be released May 21, 2026, ahead of live presentations from May 30–June 2
Financial Impact
Non-financial but high strategic value; potential to drive partnership interest and investor confidence
Risk Factors
- Data remains preliminary and subject to change after final verification
- Oral presentation does not guarantee positive or clinically meaningful results
- Market may react negatively if data shows limited efficacy or safety concerns
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278156 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 27, 2026 5w ago | Insider Buy | $9.45 $8.50 | ▼ −10.05% | ▼ −10.31% | $7.72 (−18.25%) |
Aug 26, 2026 5w ago | 6-K | $9.36 $8.33 | ▲ +11.00% | ▲ +10.50% | $7.72 (+17.47%) |
Aug 18, 2026 6w ago | 6-K | $9.09 $8.82 | ▼ −2.97% | ▼ −1.98% | $7.72 (−15.02%) |
Aug 18, 2026 6w ago | Press Release | $9.09 $8.82 | ▼ −2.97% | ▼ −1.98% | $7.72 (−15.02%) |
Jun 2, 2026 17w ago | 6-K | $10.04 $9.85 | ▼ −1.89% | ▼ −0.33% | $7.72 (−23.06%) |
Jun 1, 2026 17w ago | 6-K | $11.14 $10.13 | ▼ −9.07% | ▼ −7.77% | $7.72 (−30.66%) |
Jun 1, 2026 17w ago | Press Release | $11.14 $10.13 | ▼ −9.07% | ▼ −7.77% | $7.72 (−30.66%) |
May 31, 2026 17w ago | Press Release | $11.14 $10.13 | ▼ −9.07% | ▼ −7.77% | $7.72 (−30.66%) |
May 30, 2026 17w ago | Press Release | $11.14 $10.13 | ▼ −9.07% | ▼ −7.77% | $7.72 (−30.66%) |
May 12, 2026 20w ago | 6-K | $11.39 $8.87 | ▲ +22.12% | ▲ +20.40% | $7.72 (+32.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access